Dataset from A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma

This is a Phase III, multicenter, open-label, three-arm, randomized study in participants
with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at
least two prior regimens of cytotoxic chemotherapy for metastatic disease. The study compares
regorafenib, a standard of care therapy in this setting, to cobimetinib plus atezolizumab and
atezolizumab monotherapy.